How to use BRONQUIDIAZINA CR SUSTAINED-RELEASE ORAL SUSPENSION
Translated with AI
This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.
Show originalContents of the leaflet
Introduction
Leaflet: information for the user
Bronquidiazina CR oral suspension
(trimethoprim/sulfamethoxazole/bromhexine hydrochloride/Tolu balsam fluid extract)
Read the entire leaflet carefully before starting to take this medication, as it contains important information for you.
- Keep this leaflet, as you may need to read it again.
- If you have any doubts, consult your doctor or pharmacist.
- This medication has been prescribed to you only, and you should not give it to others, even if they have the same symptoms as you, as it may harm them.
- If you experience side effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. See section 4.
Contents of the leaflet
- What is Bronquidiazina CR and what is it used for
- What you need to know before taking Bronquidiazina CR
- How to take Bronquidiazina CR
- Possible side effects
- Storage of Bronquidiazina CR
- Package contents and additional information
1. What is Bronquidiazina CR and what is it used for
Bronquidiazina CR contains four different active ingredients. Two of them (trimethoprim/sulfamethoxazole) belong to a group of medications called antibiotics that eliminate bacteria that cause infections. These two antibiotics are associated with bromhexine and Tolu balsam syrup, with mucolytic and balsamic-expectorant activity, respectively, reducing the viscosity of mucous secretions and facilitating their elimination.
Bronquidiazina CR is indicated in children over 2 years, adolescents, and adults, for the oral treatment of other infections caused by microorganisms sensitive to the trimethoprim/sulfamethoxazole combination, such as: acute bronchitis and exacerbation of chronic bronchitis, pneumonias, middle ear infections, and sinusitis.
Official recommendations on the proper use of antibacterial agents should be taken into account.
2. What you need to know before taking Bronquidiazina CR
Do not take Bronquidiazina CR
- If you are allergic to the active ingredients of this medication: trimethoprim, sulfamethoxazole, bromhexine, Tolu balsam syrup, or any of the other components of this medication (listed in section 6).
- If you are allergic to sulfonamides, medications that contain sulfonamides are antidiabetic medications of the sulfonylurea group (e.g., gliclazide, glibenclamide) or diuretics of the thiazide group (hydrochlorothiazide).
- In children under 2 years.
- If you have or think you have acute porphyria (a blood disease in which hemoglobin is not produced properly).
- If you are or think you may be pregnant or breastfeeding.
- In combination with dofetilide (a medication used to control irregular or rapid heartbeats).
- If you have advanced liver or kidney failure.
- Do not take Bronquidiazina CR if anyof the above points apply to you. If you are not sure, before starting treatment, talk to your doctor or pharmacist.
Warnings and precautions
Life-threatening skin rashes have been described (Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, and acute febrile neutrophilic dermatosis or Sweet's syndrome) with the use of this medication.
The period of highest risk of severe skin reactions is during the first few weeks of treatment. Initially, they appear as red spots or circular patches, often with a central blister. Other additional signs that may appear are sores in the mouth, throat, nose, genitals, and conjunctivitis (swollen and red eyes). These life-threatening skin rashes are often accompanied by flu-like symptoms. The rash can progress to generalized blistering or skin peeling.
If you have developed Stevens-Johnson syndrome, toxic epidermal necrolysis, or acute febrile neutrophilic dermatosis with the use of cotrimoxazole (trimethoprim/sulfamethoxazole) or bromhexine, you should not use this medication again at any time.
Stop taking Bronquidiazina CR and go immediately to a doctor, informing them of the use of this medication, if you develop red and scaly lesions with bumps under the skin and blisters, or experience any of the above symptoms.
Haemophagocytic lymphohistiocytosis
Very rare cases of excessive immune reactions have been reported due to unregulated activation of white blood cells, causing inflammation (haemophagocytic lymphohistiocytosis), which can be potentially fatal if not diagnosed and treated early.
Contact your doctor immediatelyif you experience multiple symptoms such as fever, swollen lymph nodes, weakness, dizziness, shortness of breath, unexpected worsening of cough, bruising, or skin rash with or without a slight delay.
Consult your doctor or pharmacist before starting to take Bronquidiazina CR:
- In elderly patients, with kidney failure, or with HIV infection, as they may be more likely to experience severe effects.
- If you are asthmatic or have a history of asthma, have a severe respiratory disease, or have difficulty coughing.
- If you have diseases that predispose you to gastrointestinal bleeding, such as stomach or duodenal ulcers.
- If you have kidney problems (known kidney failure). Your doctor should take special measures. To ensure adequate renal elimination, the patient should receive adequate fluid intake and the urinary pH should be maintained within normal limits, avoiding acidification or alkalization of the urine.
- If you have liver problems (severe liver parenchymal damage).
- If you have severe blood disorders, except in cases where there is close medical supervision.
- If you have a deficiency of an enzyme called glucose-6-phosphate dehydrogenase (G-6-PD).
- If you take this medication for a long time or if you have a folate deficiency or are an elderly patient, your doctor may request that you have blood tests to perform blood counts.
- If you are at risk of hyperkalemia (high potassium levels) and hyponatremia (low sodium levels), your doctor will consider the need to monitor potassium and sodium levels in the blood.
- If you have phenylketonuria (a metabolic disease that affects the enzyme phenylalanine), as the administration of trimethoprim alters phenylalanine metabolism. This is not a problem in patients with an adequate restrictive diet.
- This medication may interfere with the results of some laboratory tests.
This medication should not be used to treat streptococcal pharyngitis (Group A beta-hemolytic S. pyogenes).
During treatment with this medication, excessive exposure to the sun or the use of sunlamps should be avoided.
Bronquidiazina CR should not be taken with antitussive medications (for cough) or those that reduce bronchial secretions, as this may cause an accumulation of fluidized mucus.
Other medications and Bronquidiazina CR
Tell your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medication. Bronquidiazina CR may enhance the effect and/or toxicity of some medications. It is essential that you inform your doctor if you are taking or have recently taken any of the following medications:
- Medications used to control heart rhythm (class III antiarrhythmics), such as dofetilide.
- Medications that are folic acid antagonists, such as phenytoin (used to treat epilepsy) and methotrexate (used to treat various types of cancer and also to treat rheumatoid arthritis). If trimethoprim/sulfamethoxazole and phenytoin are administered, the excessive effect of phenytoin should be taken into account. If Bronquidiazina CR is administered with methotrexate, the administration of a folate supplement should be considered.
- Medications used to increase urine elimination: diuretics (especially thiazides).
- Oral anticoagulant medications such as warfarin. Careful monitoring of anticoagulant treatment is recommended during the use of Bronquidiazina CR.
- Certain medications used to control blood sugar levels: oral hypoglycemics or antidiabetics (sulfonylurea).
- Medications used to treat heart problems (digoxin).
- Medications used to treat infections caused by certain parasites (pyrimethamine).
- Certain medications used to treat the human immunodeficiency virus (HIV): antiretrovirals (lamivudine, zidovudine). Monitoring of blood parameters should be considered.
- Medications used in transplants: immunosuppressants (cyclosporine).
- Medications that produce hyperkalemia (increased potassium in the blood).
- Drugs such as procainamide, amantadine.
Taking Bronquidiazina CR with food and drinks
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Trimethoprim, sulfamethoxazole, and bromhexine cross the placenta; their safety in pregnant women has not been established. This medication should be avoided during pregnancy.
When this medication is administered to the mother before childbirth, there may be a theoretical risk of kernicterus (a severe neurological complication due to increased bilirubin in the blood) in the newborn. This theoretical risk is particularly important in children with a higher risk of hyperbilirubinemia, such as premature infants or those with glucose-6-phosphate dehydrogenase deficiency. The administration of this medication should be avoided in the final stages of pregnancy and in breastfeeding mothers, when the mothers or children have or are at particular risk of developing hyperbilirubinemia.
Trimethoprim, sulfamethoxazole, and bromhexine are excreted in breast milk; therefore, this medication should be avoided during breastfeeding.
Driving and using machines
Bronquidiazina CR contains saccharose, sodium benzoate, sodium, methylparaben (E-218), propylparaben (E-216), and ethanol.
This medication contains saccharose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
This medication contains 1 mg of sodium benzoate per ml of suspension.
This medication may cause allergic reactions (possibly delayed) because it contains methylparaben (E-218) and propylparaben (E-216).
This medication contains 0.0014 mg of alcohol (ethanol) per ml of dose. The amount in 1 ml of this medication is equivalent to less than 1 ml of beer or 1 ml of wine.
The small amount of alcohol in this medication does not produce any noticeable effect.
This medication contains less than 23 mg of sodium (1 mmol) per 7.5 ml of suspension, which is essentially "sodium-free".
3. How to take Bronquidiazina CR
Follow the administration instructions of the medication indicated by your doctor exactly. If in doubt, consult your doctor or pharmacist again.
Your doctor will prescribe the most suitable dose and duration according to the type of infection and its severity. The recommended standard dose is:
Treatment of acute infections:
Adults and children 12 years or older:15 ml every 12 hours.
Children 2-5 years:3.8 ml every 12 hours.
Children 6-11 years:7.5 ml every 12 hours.
If after 7 days of treatment, no clinical improvement is observed, the patient will be reevaluated.
The total daily dose should not exceed 320 mg of trimethoprim and 1600 mg of sulfamethoxazole.
The total daily dose of bromhexine should not exceed 6 mg per day in children between 2-5 years, 12 mg per day in children between 6 and 11 years, and 48 mg per day in adults and adolescents 12 years or older.
Special dosages
Elderly patients:(see section 2: Warnings and precautions). If not otherwise specified, the standard dose will be used.
Patient with renal failure
Adults and adolescents (≥12 years):
Creatinine clearance (ml/min) | Recommended dose |
> 30 | Standard dose |
15-30 | Half of the standard dose |
< 15 | Not recommended |
Your doctor may perform blood tests every 2-3 days to measure the amount of medication in the blood.
Route and method of administration
Oral route. For proper administration of this medication, it is recommended to shake well before use.
Duration of treatment
Your doctor will indicate the duration of your treatment with Bronquidiazina CR. Do not stop treatment prematurely. If you need to take Bronquidiazina CR for long periods, your doctor may request blood tests and prescribe folic acid supplements (vitamin) during the time you take this medication.
If you take more Bronquidiazina CR than you should
Symptoms of overdose include: nausea, vomiting, dizziness, and confusion.
In acute overdose with trimethoprim, bone marrow depression has been observed.
If vomiting does not occur, it should be induced. Gastric lavage should be performed. Depending on the state of renal function, the administration of fluids is recommended if urine elimination is low.
Both trimethoprim and sulfamethoxazole are dialyzable by hemodialysis. Peritoneal dialysis is not effective.
In case of overdose or accidental ingestion, consult the Toxicology Information Service. Phone: 91 562 04 20.
If you forget to take Bronquidiazina CR
Do not take a double dose to make up for forgotten doses.
4. Possible Adverse Effects
Like all medicines, Bronquidiazina CR can produce adverse effects, although not all people suffer from them.
Severe Adverse Effects
Call emergency services immediately if you experience multiple symptoms such as fever, very low blood pressure, or increased heart rate after taking this medication, as it may be a symptom of shock.
Stop taking Bronquidiazina CR and contact your doctor immediatelyif you have the following signs compatible with an allergic reaction. The possibility of having a severe allergic reaction is very rare (it can affect up to 1 in 10,000 people).
- Difficulty breathing
- Dizziness
- Facial swelling
- Swelling of the mouth, tongue, or throat that can be painful and cause difficulty swallowing
- Chest pain
- Red spots on the skin
Contact a doctor as soon as possible if you experience any of the following adverse reactions:
- Severe skin reactions that can threaten the patient's life (frequency not known: cannot be estimated from available data): purple-colored, raised, and painful blisters on the extremities and sometimes on the face and neck, with fever (Sweet's syndrome); as well as red and scaly eruptions with bumps under the skin and blisters (acute generalized exanthematous pustulosis), (see section 2: Warnings and Precautions).
- Drug hypersensitivity reactions accompanied by systemic symptoms (DRESS), which occur with a rare frequency (can affect up to 1 in 1,000 people) but can be life-threatening. In this type of reaction, you may develop symptoms similar to the flu: fever, skin rash, lymph node inflammation, and altered blood test results.
- Skin eruptions that can appear with a very rare frequency (can affect up to 1 in 10,000 people) but can be life-threatening: Stevens-Johnson syndrome, toxic epidermal necrolysis (see section 2: Warnings and Precautions).
In addition, the following adverse effects have been described with this medication, classified by order of frequency:
- Very frequent (can affect more than 1 in 10 people): hyperkalemia (elevated potassium level).
- Frequent (can affect up to 1 in 10 people): candidiasis (overgrowth of the Candida fungus), headache, nausea, diarrhea, and skin eruptions.
- Infrequent (can affect up to 1 in 100 people): vomiting, pain in the upper abdomen.
- Rare (can affect up to 1 in 1,000 people): bronchospasm, exanthema, urticaria.
- Very rare (can affect up to 1 in 10,000 people): leukopenia, neutropenia, and agranulocytosis (decrease in the total number or a certain type of white blood cells), megaloblastic or immune hemolytic anemia (decrease in the number of red blood cells with or without an increase in their size), aplastic anemia (insufficiency of the bone marrow to produce different types of cells), methemoglobinemia (inability of hemoglobin to transport oxygen), eosinophilia (abnormally high amount of a certain type of white blood cells), purpura (red spots on the skin), hemolysis (breakdown of red blood cells), serum sickness (hypersensitivity reaction similar to an allergy), anaphylaxis (severe allergic reaction), allergic myocarditis (allergic reaction that affects the heart), angioedema (fluid retention in the skin and mucous membranes), fever, allergic vasculitis (inflammation that affects mainly small veins), polyarteritis nodosa (vascular disease), systemic lupus erythematosus (immune system disease), hypoglycemia (decrease in blood glucose), hyponatremia (decrease in sodium in the blood), anorexia (metabolic disorder), depression, hallucinations, aseptic meningitis, convulsions, peripheral neuritis (lesion and deterioration of peripheral nerves), ataxia (loss of coordination), vertigo, tinnitus (ringing in the ears), dizziness, cough, difficulty breathing, pulmonary infiltrates, glossitis (inflammation of the tongue), stomatitis (lesions in the mouth), pseudomembranous colitis (inflammation of the colon), pancreatitis (inflammation of the pancreas), hepatobiliary disorders (alteration of liver function), photosensitivity (skin reaction produced by interaction with light), exfoliative dermatitis (severe inflammation of the entire skin surface), fixed drug eruption (allergic reaction), erythema multiforme (allergic reaction that affects the skin), arthralgia (joint pain), myalgia (muscle pain), alteration of renal function, uveitis (inflammation of the eye).
If you experience adverse effects, consult your doctor or pharmacist, even if they are adverse effects that do not appear in this prospectus.
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
5. Storage of Bronquidiazina CR
No special storage conditions are required.
Keep this medication out of sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Medicines should not be thrown away through the sewers or in the trash. Deposit the packaging and medications you no longer need at the pharmacy's SIGRE point. In case of doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. This way, you will help protect the environment.
6. Package Contents and Additional Information
Composition of Bronquidiazina CR
- The active ingredients are trimethoprim, sulfamethoxazole, bromhexine, and fluid extract of Tolu balsam. Each 7.5 ml of suspension contains 80 mg of trimethoprim, 400 mg of sulfamethoxazole, 4 mg of bromhexine hydrochloride, and 32.5 mg of fluid extract of Tolu balsam.
- The other components are: glycerin, sucrose, xanthan gum, sodium saccharin, methyl parahydroxybenzoate (E-218), sodium benzoate, propyl parahydroxybenzoate (E-216), simethicone, anise essence, ethanol (derived from the fluid extract of Tolu balsam), and water.
Appearance of the Product and Package Contents
White, homogeneous oral suspension with an aniseed flavor.
Glass bottle with a polypropylene/polyethylene high-density (PP/HDPE) cap with a child-proof closure, containing 150 ml of oral suspension and a dosing measure.
Marketing Authorization Holder
Faes Farma, S.A.
Autonomia Etorbidea, 10
48940 Leioa (Bizkaia)
Spain
Manufacturer
Faes Farma, S.A.
Bizkaia Science and Technology Park
Ibaizabal Bidea, Building 901
48160 Derio (Bizkaia)
Spain
Date of the Last Revision of this Prospectus:July 2025
-
- Country of registration
- Dosage formORAL SOLUTION/SUSPENSION, {"pl":null}
- ATC codeR05CZ95
- Active substance
- Prescription requiredYes
- Manufacturer
- This information is for reference only and does not constitute medical advice. Always consult a doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to BRONQUIDIAZINA CR SUSTAINED-RELEASE ORAL SUSPENSIONDosage form: ORAL SOLUTION/SUSPENSION, 2.66 g; 0.05 g; 0.54 g/mlActive substance: Expectorants, excl. combinations with cough suppressantsManufacturer: Desma Laboratorio Farmaceutico S.L.Prescription requiredDosage form: ORAL SOLUTION/SUSPENSION, -Active substance: Expectorants, excl. combinations with cough suppressantsManufacturer: Industria Quimica Y Farmaceutica Vir S.A.Prescription requiredDosage form: ORAL SOLUTION/SUSPENSION, 7 mg/mlActive substance: Hederae helicis foliumManufacturer: Engelhard Arzneimittel Gmbh & Co. KgPrescription not required
Online doctors for BRONQUIDIAZINA CR SUSTAINED-RELEASE ORAL SUSPENSION
Discuss questions about BRONQUIDIAZINA CR SUSTAINED-RELEASE ORAL SUSPENSION, including use, safety considerations and prescription review, subject to medical assessment and local regulations.
Get BRONQUIDIAZINA CR SUSTAINED-RELEASE ORAL SUSPENSION Prescription Online
Fill in a 2-min form
Tell us your symptoms, history, and what medicine you're requesting.
Pick a doctor or let us assign
Choose a specialist or we'll match you with the next available doctor.
Doctor reviews your case
Usually within 30 minutes. They may ask follow-up questions via chat.
Collect from any pharmacy
Electronic prescription sent to your email — valid across Spain.
Frequently Asked Questions
BRONQUIDIAZINA CR SUSTAINED-RELEASE ORAL SUSPENSION requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
The active ingredient in BRONQUIDIAZINA CR SUSTAINED-RELEASE ORAL SUSPENSION is Expectorants, excl. combinations with cough suppressants. This information helps identify medicines with the same composition but different brand names.
BRONQUIDIAZINA CR SUSTAINED-RELEASE ORAL SUSPENSION is manufactured by Faes Farma S.A.. Pharmacy brands and packaging may differ depending on the distributor.
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether BRONQUIDIAZINA CR SUSTAINED-RELEASE ORAL SUSPENSION is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
Spain has a well-developed healthcare infrastructure across major cities such as Madrid, Barcelona, Valencia, and Seville. Pharmacies are widely available and operate under strict regulations, ensuring access to prescribed medications.
You can buy BRONQUIDIAZINA CR SUSTAINED-RELEASE ORAL SUSPENSION in Madrid, Barcelona, Seville, or Valencia at any local pharmacy with a valid prescription.
To obtain a prescription, you can use Oladoctor:
Other medicines with the same active substance (Expectorants, excl. combinations with cough suppressants) include BALSOPRIM 26.6mg/mL + 5.4mg/mL + 0.5mg/mL ORAL SUSPENSION, BRONCOVIR ORAL SUSPENSION, ABRILAR SYRUP. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
